Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-90009 + gilteritinib
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CC-90009 + gilteritinib is an experimental combination therapy under investigation for the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed or relapsed/refractory cases. CC-90009 (eragidomide) is a novel cereblon E3 ligase modulating drug and a first-in-class GSPT1 (G1 to S phase transition 1) degrader, acting through targeted protein degradation via the ubiquitin-proteasome system. Gilteritinib is a small molecule tyrosine kinase inhibitor that selectively inhibits FMS-like tyrosine kinase 3 (FLT3), which is commonly mutated in AML. The combination is being evaluated for synergistic anti-leukemic effects, particularly targeting FLT3-mutant AML. The primary aim is to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of the regimen[1][2][4].
- Other names
- CC-90009 + gilteritinib
02
Targets
CRBN (Cereblon)GSPT1 (G1 to S phase transition 1)FLT3 (Fms related receptor tyrosine kinase 3)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on CC-90009 + gilteritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-90009 + gilteritinib.